BLA 019991 · Novo Nordisk INC
Novolin 70/30
Insulin Recombinant Human, Insulin Susp Isophane Recombinant Human · Injection · Insulin
Last checked: Nov 20, 2026Latest source record: Nov 23, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1991
Jun 25, 1991
Approved uses
1
Original approval plus efficacy supplements
Registered trials
100
15 Phase 3, 0 recruiting
FAERS reports
5,946
3,872 serious, 612 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Feb 6, 2023.
NOVOLIN 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. Limitations of Use: In NOVOLIN 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. NOVOLIN 70/30 is a mixture of human insulin isophane, an intermediate-acting human insulin, and human insulin, a short-acting human insulin, indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. ( 1 )
Mechanism: The primary activity of insulin, including NOVOLIN 70/30, is the regulation of glucose metabolism. Insulins lower blood glucose by stimulating peripheral glucose uptake, especially by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulin inhibits lipolysis and proteolysis, and enhances protein synthesis.
Therapeutic areas: Cardiovascular and metabolic
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jun 25, 1991 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- NOVOLIN 70/30 · INSULIN RECOMBINANT HUMAN 30 UNITS/ML; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN 70 UNITS/ML · INJECTABLE, INJECTION · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Insulin Recombinant Human" as an intervention, any sponsor and status, largest first.
- The Diabetes Prevention Trial of Type 1 Diabetes (DPT-1)Pivotal-lookingCompleted
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT00004984 · 711 participants · Start Feb 1994 · Primary completion Jun 2003
Drug: Parenteral Insulin; Oral Insulin and 1 more · For: Diabetes Mellitus, Type 1
Sites: Los Angeles, California; San Francisco, California; Stanford, California · 15 sites in all
- Assessment of Mechanisms of Improved Wound HealingPivotal-lookingCompleted
The University of Texas Medical Branch, GalvestonAcademic, hospital or other
NCT00673309 · 644 participants · Start Jul 2000 · Primary completion Apr 2011
Drug: Insulin High Dose; oxandrolone and 8 more · For: Burns
Sites: Galveston, Texas
- Combination of Corticotherapy and Intensive Insulin Therapy for Septic ShockPivotal-lookingCompleted
University of VersaillesAcademic, hospital or other
NCT00320099 · 508 participants · Start Jan 2006 · Primary completion Jan 2009
Drug: recombinant human insulin; hydrocortisone and 2 more · For: Septic Shock
Sites: Bobigny, France; Bondy, France; Grenoble, France · 8 sites in all
- CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)Pivotal-lookingCompleted
Halozyme TherapeuticsIndustry
NCT01848990 · 456 participants · Start Mar 2013 · Primary completion Feb 2014
Drug: Commercial Hylenex® recombinant (hyaluronidase human injection); Precommercial Hylenex recombinant (hyaluronidase human injection) and 3 more · For: Type 1 Diabetes Mellitus
Sites: Concord, California; Encino, California; Escondido, California · 39 sites in all
- Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic PatientsPivotal-lookingCompleted
Sun Yat-sen UniversityAcademic, hospital or other
NCT01147627 · 416 participants · Start Aug 2010 · Primary completion Aug 2012
Drug: exenatide injection; Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R and 1 more · For: Diabetes Mellitus, Type 2; Newly Diagnosed
Sites: Beijing, China; Guangzhou, China; Qingyuan, China · 25 sites in all
- A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 DiabetesPivotal-lookingTerminated
Diamyd Medical ABIndustry
NCT05018585 · 321 participants · Start May 19, 2022 · Primary completion Jun 24, 2026
Drug: Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®; Placebo · For: Type 1 Diabetes Mellitus
Sites: Newport Beach, California; Palo Alto, California; San Diego, California · 60 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT00642941 · 317 participants · Start Dec 18, 2007 · Primary completion Feb 19, 2014
Drug: RG1507 · For: Sarcoma
Sites: Duarte, California; Los Angeles, California; Santa Monica, California · 41 sites in all
- The Effect of Intensive Insulin Therapy in the Surgical Critical Care UnitPivotal-lookingCompleted
GenesysAcademic, hospital or other
NCT00282594 · 317 participants · Start Jul 2003
Drug: Novolin R (human recombinant Insulin) · For: Sepsis; Respiratory Failure; Renal Failure and 1 more
Sites: Grand Blanc, Michigan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- blood glucose increased902
- nausea354
- blood glucose decreased349
- drug ineffective291
- dyspnoea287
- dizziness255
- fatigue231
- diarrhoea224
- death222
- asthenia208
- renal failure202
- weight decreased202
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 113 |
| 2005 | 155 |
| 2006 | 247 |
| 2007 | 183 |
| 2008 | 136 |
| 2009 | 212 |
| 2010 | 247 |
| 2011 | 234 |
| 2012 | 253 |
| 2013 | 217 |
| 2014 | 282 |
| 2015 | 684 |
| 2016 | 430 |
| 2017 | 445 |
| 2018 | 513 |
| 2019 | 449 |
| 2020 | 242 |
| 2021 | 223 |
| 2022 | 163 |
| 2023 | 98 |
| 2024 | 197 |
| 2025 | 155 |
| 2026 | 68 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Novolin 70-30 (Insulin NPh Hum/Reg Insulin Hm)
2024 spending
$26.9M
Beneficiaries
44,872
170,702 claims
Per beneficiary
$600
$4.45 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $142,968,867 |
| 2021 | $132,943,279 |
| 2022 | $125,778,588 |
| 2023 | $112,846,649 |
| 2024 | $26,929,490 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Use of a premixed insulin regimen (Novolin 70/30) to replace self-mixed insulin regimens.
Aronoff S, Goldberg R, Kumar D, et al. · Clin Ther 1994 · Clinical Trial, Multicenter Study
Sponsor: Novo Nordisk
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.